T-cell Based Immunotherapy for Treatment of Patients Squamous Cell Carcinoma in the Oral Cavity. A Pilot Study.
- Patients with histological proven squamous cell carcinoma T3 or more in the oral
cavity planned for primary surgery. Performance Status 0 to 1. Acceptable CBC and
blood chemistry results. Acceptable organ functions.
- Patients with a history of any other malignancies less than five years ago. Brain
metastases. Other significant illness including severe allergy, asthma, DM, angina
pectoris, congestive heart failure, chronic infections, or active autoimmune disease.
Treatment with immune suppressive drugs, experimental drugs, or antineoplastic drugs.
Type of Study:
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Time Frame:
week 0 to 20
Inge Marie Svane, Professor, MD
Department of Oncology, Copenhagen University Hospital, Herlev, Herlev Ringvej 75, DK-2730 Herlev, Denmark
Denmark: Danish Medicines Agency
- Squamous Cell Carcinoma
- Head and Neck Cancer
- Carcinoma, Squamous Cell
- Head and Neck Neoplasms